For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Scope of the Report:
This report focuses on the Bio Pharma Buffer in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The key players are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE, Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL and so on. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share in 2016.
Despite the presence of competition problems, due to the global recovery trend is clear, investors are still optimistic about this area, the future will still have more new investment enter the field. Even so, the market is intensely competitive. The study group recommends the new entrants just having money but without technical advantage and upstream and downstream support do not to enter into this field.
The worldwide market for Bio Pharma Buffer is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Alfa Aesar (Thermo Fisher)
- GE Healthcare
- Promega Corporation
- Hamilton Company
- XZL BIO-TECHNOLOGY
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Phosphates Type
- Acetates Type
- TRIS Type
Market Segment by Applications, can be divided into
- Research Institution
- Pharmaceutical Industry
There are 15 Chapters to deeply display the global Bio Pharma Buffer market.
Chapter 1, to describe Bio Pharma Buffer Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Bio Pharma Buffer, with sales, revenue, and price of Bio Pharma Buffer, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Bio Pharma Buffer, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Bio Pharma Buffer market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Bio Pharma Buffer sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source